Patents Assigned to Paracelsus Neuroscience I, LLC
  • Use of senicapoc for treatment of neuropathic pain
    Patent number: 11439607
    Abstract: A method is disclosed of treating pain with senicapoc, a potent Ca2+-activated K+ channel, KCa3.1 antagonist in CNS-resident microglia. Senicapoc is shown to cause in a decrease of IL-1? and NO release from microglia cells vivo and in vitro. Because of contribution of KCa3.1 to neuropathological processes, senicapoc is useful in the treatment of chronic, neuropathic, visceral, and inflammatory pain and the reversal of tactile allodynia.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: September 13, 2022
    Assignee: Paracelsus Neuroscience I, LLC
    Inventors: Roland Staal, Thomas Möller